Article
Endocrinology & Metabolism
Mark Warren, Bruce Bode, Jang I. Cho, Rong Liu, Janet Tobian, Thomas Hardy, Farai Chigutsa, Moshe Phillip, Barry Horowitz, Debra Ignaut
Summary: The study found that in patients with type 1 diabetes using CSII, URLi was more effective in improving postprandial glucose control and reducing time spent in hypoglycemia compared to lispro.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Jianhua Ma, Xiang Yan, Qiong Feng, Wei Liu, Federico Perez Manghi, Pedro Garcia-Hernandez, Guixia Wang, Jianwei Xu, Yuan Yuan, Zhiguang Zhou
Summary: The study aimed to evaluate the efficacy and safety of ultra-rapid lispro (URLi) compared to insulin lispro in Chinese patients with type 1 diabetes. The findings showed that URLi demonstrated better control of postprandial glucose excursions and was noninferior to insulin lispro in terms of glycated hemoglobin control in this population.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Ronnie Aronson, Torben Biester, Jennifer Leohr, Robyn Pollom, Helle Linnebjerg, Elizabeth Smith LaBell, Qianyi Zhang, David E. Coutant, Thomas Danne
Summary: This study compared the pharmacokinetics, glucodynamics and tolerability of ultra rapid lispro (URLi) and Humalog in children, adolescents and adults with type 1 diabetes mellitus. The results showed that URLi achieved faster onset of action, reduced early t(max), increased exposure in the first 15 minutes, and decreased exposure after 3 hours compared with Humalog. URLi also resulted in greater reduction of postprandial glucose levels at 1 hour.
DIABETES OBESITY & METABOLISM
(2023)
Article
Public, Environmental & Occupational Health
Keyu Guo, Jiaqi Li, Liyin Zhang, Jianan Ye, Li Fan, Zhiyi Ding, Qin Zhou, Xia Li, Lin Yang, Zhiguang Zhou
Summary: This study compared the efficacy of continuous subcutaneous insulin infusion (CSII) therapy with multiple daily injection (MDI) therapy in Chinese patients with type 1 diabetes mellitus (T1DM). The results showed that CSII therapy was associated with lower HbA1c levels and better glycemic outcomes. However, it did not improve the risk of hypoglycemia.
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Nutrition & Dietetics
Carolien Ruijgrok, Ellen E. Blaak, Leonie Egli, Pierre Dussort, Sophie Vinoy, Simone P. Rauh, Joline W. Beulens, M. Denise Robertson, Marjan Alssema
Summary: This study aimed to quantify the relationship of acute glucose and insulin postprandial responses with longer-term effects on diabetes-related risk factors through a systematic review and meta-analysis of dietary intervention studies. Results showed that changes in acute postprandial glucose responses were associated with changes in fasting plasma glucose, but not with fasting insulin. Further research is needed to fully understand the impact of acute postprandial changes on long-term risk factors.
EUROPEAN JOURNAL OF NUTRITION
(2021)
Article
Engineering, Biomedical
Bo Zhi Chen, Wen Xuan Li, Yun Hao Feng, Xiao Peng Zhang, Jie Jiao, Zhuo Lin Li, Vahideh Nosrati-Siahmazgi, Mohammad-Ali Shahbazi, Xin Dong Guo
Summary: This study examined the combination of insulin-loaded dissolving microneedles (MNs) with insulin aspart (IAsp) or insulin degludec (IDeg) therapy for diabetes treatment. The results showed that the insulin-loaded MNs provided comparable blood glucose control abilities to subcutaneous injections in diabetic rats. The MNs have the potential to improve glycemic control and patient compliance, while reducing injection pain.
ACTA BIOMATERIALIA
(2023)
Article
Pharmacology & Pharmacy
Min-Hwan Kim, Ju-Hwan Park, Duy-Thuc Nguyen, Sungyun Kim, Da In Jeong, Hyun-Jong Cho, Dae-Duk Kim
Summary: An HAase inhibitor-incorporated hyaluronic acid hydrogel was designed to reduce toxicity risk and slow biodegradation rate in subcutaneous tissue. The hydrogel, formulated with Quercetin as an HAase inhibitor and quetiapine as a model drug, exhibited sustained drug release and improved pharmacokinetic parameters in rats following subcutaneous injection. All results supported the designed hydrogel as a biocompatible formulation for sustained drug delivery.
Article
Endocrinology & Metabolism
Jennifer Leohr, Mary Anne Dellva, Elizabeth Labell, David E. Coutant, Jorge Arrubla, Leona Plum-Moerschel, Eric Zijlstra, Tsuyoshi Fukuda, Thomas Hardy
Summary: During episodes of hyperglycaemia commonly experienced in people with type 1 diabetes, URLi provided a faster recovery versus Humalog from a missed mealtime bolus or during basal insulin suspension. URLi shows significant acceleration of insulin absorption versus Humalog when boluses are administered by subcutaneous infusion or injection.
DIABETES OBESITY & METABOLISM
(2023)
Article
Nutrition & Dietetics
Farshad Teymoori, Hossein Farhadnejad, Nazanin Moslehi, Parvin Mirmiran, Ebrahim Mokhtari, Fereidoun Azizi
Summary: The study revealed that a diet high in GL, GI, II, and IL can increase the incidence of diabetes. Glycemic and insulin load are stronger predictors of diabetes risk compared to glycemic index and insulin index.
CLINICAL NUTRITION
(2021)
Article
Endocrinology & Metabolism
Jennifer Leohr, Christof Kazda, Rong Liu, Shobha Reddy, Mary Anne Dellva, Mark Matzopoulos, Mei Teng Loh, Thomas Hardy, Oliver Klein, Christoph Kapitza
Summary: The study showed that URLi had better postprandial glucose control compared with Humalog, with increased insulin exposure and shortened time to peak concentration. Overall, URLi resulted in significant reduction in postprandial glucose excursion over 5 hours with different meal-to-dose timings.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Christof Kazda, Jennifer Leohr, Rong Liu, Shobha Reddy, Mary Anne Dellva, Mei Teng Loh, Thomas Hardy, Leona Plum-Morschel
Summary: This study compared the pharmacokinetics, glucodynamics, and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro and Humalog in patients with type 1 diabetes mellitus. Results showed that URLi had faster insulin absorption and better postprandial glucose reduction compared to Humalog, maintained stable profiles after two weeks of daily dosing, and had similar hypoglycemic events as Humalog.
DIABETES OBESITY & METABOLISM
(2022)
Article
Nutrition & Dietetics
Yoshihiro Tsuchiya, Joto Yoshimoto, Hiroto Kobayashi, Sho Ishii, Mikiya Kishi
Summary: In this study, the usefulness of yellow pea pasta (YPP) in blood sugar control and reducing health risks was investigated. The results showed that YPP prepared with a 0.75% salt concentration tasted saltier than conventional semolina wheat pasta. Moreover, YPP consumption resulted in lower elevation in blood glucose and insulin secretion, while maintaining similar levels of satiety. Additionally, YPP was found to suppress elevated insulin levels at the second meal.
Article
Endocrinology & Metabolism
Wei Song, Jianxuan Wen, Jinming Zhang, Meng Luo, Yue Hu, Yu Zhang, Guanjie Fan, Ling Zhao
Summary: This study investigated the short-term effect of continuous subcutaneous insulin infusion (CSII) and multiple daily injection (MDI) in perioperative patients with type 2 diabetes mellitus (T2DM) using data envelopment analysis (DEA). The results showed that CSII effectively controlled blood glucose levels and reduced perioperative hospitalization time for T2DM patients, suggesting its clinical benefit.
JOURNAL OF DIABETES RESEARCH
(2023)
Article
Endocrinology & Metabolism
Takahiro Ishii, Akihiro Katayama, Mihiro Sue, Remi Kuribayashi, Masafumi Tenta, Yuichi Matsushita, Masaya Takeda, Izumi Iseda, Satomi Tani, Kazuyuki Hida
Summary: Subcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control. Treatment with ultra-rapid insulin lispro has shown effectiveness in cases of subcutaneous insulin resistance syndrome, providing similar glucose-lowering effects and insulin absorption as compared to insulin lispro plus heparin.
JOURNAL OF DIABETES INVESTIGATION
(2022)
Article
Endocrinology & Metabolism
Bruce Bode, Satish Garg, Paul Norwood, Cristobal Morales, Thomas Hardy, Rong Liu, Debra Ignaut
Summary: URLi was found to be compatible with insulin pump use and had a safety profile similar to lispro in patients with type 1 diabetes. There was no significant difference in the rate of infusion set failures between URLi and lispro, but URLi was associated with a higher rate of premature infusion set changes. The study also showed a trend toward improved glycemic control with URLi treatment and a higher incidence of infusion site reactions.
DIABETES TECHNOLOGY & THERAPEUTICS
(2021)
Meeting Abstract
Endocrinology & Metabolism
Richard E. Pratley, Jahoon Kang, In Young Choi, Michael E. Trautmann, Marcus Hompesch, Kun-Ho Yoon, Christopher H. Sorli
Article
Endocrinology & Metabolism
Matthew C. Riddle, Rajaa Nahra, Jenny Han, Jessica Castle, Kathryn Hanavan, Marcus Hompesch, David Huffman, Poul Strange, Peter OEhman
Review
Medicine, General & Internal
Marcus Hompesch, Dhiren K. Patel, James R. LaSalle, Geremia B. Bolli
POSTGRADUATE MEDICINE
(2019)
Meeting Abstract
Endocrinology & Metabolism
Richard E. Pratley, Stephan Jacob, Jahoon Kang, Michael E. Trautmann, Marcus Hompesch, Oakpil Han, John A. Stewart, Ike Ogbaa, Christopher H. Sorli, Kun-Ho Yoon
Meeting Abstract
Endocrinology & Metabolism
George E. Dailey, Julio Rosenstock, Cristobal Morales, Ulrich Wendisch, Michael E. Trautmann, Marcus Hompesch, In Young Choi, Jahoon Kang, Christopher H. Sorli, Ike Ogbaa, John A. Stewart, Kun-Ho Yoon
Article
Endocrinology & Metabolism
Richard E. Pratley, Jahoon Kang, Michael E. Trautmann, Marcus Hompesch, OakPil Han, John Stewart, Christopher H. Sorli, Stephan Jacob, Kun-Ho Yoon
DIABETES OBESITY & METABOLISM
(2019)
Article
Endocrinology & Metabolism
Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E. Trautmann, Marcus Hompesch, John Stewart, Christopher H. Sorli
DIABETES OBESITY & METABOLISM
(2020)
Meeting Abstract
Endocrinology & Metabolism
Linda Morrow, Michael Grimm, Carine Beysen, Geoffrey Walford, Kelly Duncan, Pranab K. Mitra, Pavan Vaddady, Marcus Hompesch
Article
Endocrinology & Metabolism
Carine Beysen, Patricia Schroeder, Eric Wu, Julie Brevard, Maria Ribadeneira, Wei Lu, Kiran Dole, Terry O'Reilly, Linda Morrow, Marcus Hompesch, Marc K. Hellerstein, Kelvin Li, Lars Johansson, Patrick F. Kelly
Summary: The study found that a dose of 3 mg FT-4101 can safely reduce hepatic de novo lipogenesis and steatosis in NAFLD patients.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E. Trautmann, Christopher H. Sorli, Ike Ogbaa, John Stewart, Linda Morrow
Summary: The effects of efpeglenatide on gastric emptying, glucose metabolism, and islet beta-cell function were comparable to liraglutide, suggesting the potential benefits of this long-acting GLP-1 RA in people with type 2 diabetes. Further studies are needed to confirm these findings.
BMJ OPEN DIABETES RESEARCH & CARE
(2021)
Article
Endocrinology & Metabolism
Richard E. Pratley, Stephan Jacob, Seungjae Baek, Michael E. Trautmann, Marcus Hompesch, OakPil Han, John Stewart, Christopher H. Sorli, Alka Shaunik, Kun-Ho Yoon
Summary: This study conducted subanalyses to explore the efficacy and safety of Efpeglenatide in different subgroups. The results showed that Efpeglenatide can improve glycemic control and body weight in patients with pre-diabetes, regardless of age, BMI, or pre-diabetes status.
BMJ OPEN DIABETES RESEARCH & CARE
(2022)
Article
Pharmacology & Pharmacy
Geoffrey A. Walford, Kelly E. Duncan, Moises Hernandez, Pavan Vaddady, Marcus Hompesch, Linda Morrow, S. Aubrey Stoch
Summary: MK-1092, a synthetic insulin dimer, has favorable properties and demonstrated significant effects in comparison to conventional insulins. The trial conducted in healthy adults and diabetes patients showed that MK-1092 was well tolerated with dose-proportional pharmacodynamic measurements.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Wonjung Shin, Marcus Hompesch, JinHee Byeon, Seohyun Kang, Jaehyuk Choi, Seungjae Baek
Summary: This study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of a novel long-acting glucagon analogue HM15136 in overweight/obese patients with co-morbidities, with and without type 2 diabetes (T2D). The results showed that HM15136 had good safety and tolerability in patients with dyslipidaemia and/or hypertension, but its use in patients with T2D may cause hyperglycaemia.
DIABETES OBESITY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Adrian Vilalta, Julio A. Gutierrez, SuZanne Chaves, Moises Hernandez, Silvia Urbina, Marcus Hompesch
Summary: Excess body fat is associated with higher risks for metabolic syndrome, type 2 diabetes mellitus, and cardiovascular disease. The distribution of body fat also contributes to increased disease risks, such as an increased level of abdominal fat being associated with a higher risk of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
ENDOCRINOLOGY DIABETES & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Brian Baker, Barbara Schaeffler, Joe Hirman, Marcus Hompesch, Susan Pederson, Jeff Smith
Summary: Eptinezumab was well tolerated and did not lead to adverse metabolic effects in overweight/obese patients or those with T1D. There were no significant differences in basal metabolic rate and insulin sensitivity between the eptinezumab and placebo groups in the two studies.
ENDOCRINOLOGY DIABETES & METABOLISM
(2021)